Engineered monocyte‐derived DCs enhance CD8+ T‐cell cytotoxicity in vitro,78 and pro‐inflammatory DCs promote Th1 responses and tumor‐specific cytotoxicity in CCA.79 Here, CD8A is linked to neoplasm.